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de novo arterial lesions
Ludovic Canaud, MD, Pierre Alric, MD, PhD, Jean-Philippe Berthet, MD, Charles Marty-Ané, MD, PhD,
Gregoire Mercier, MD, and Pascal Branchereau, MD, Montpellier, France
Background: This prospective, non-randomized study evaluated the short- and mid-term feasibility, safety, primary
patency, and limb salvage of cutting balloon percutaneous transluminal angioplasty (CB-PTA) for the treatment of
peripheral arterial occlusive disease (PAOD).
Methods and Results: All data were collected for 128 consecutive patients who underwent CB-PTA to improve infrain-
guinal arterial circulation between January 2003 and July 2007. One-hundred thirty-five limbs with PAOD (claudica-
tion, n  19; critical limb ischemia [CLI], n  116) were treated. Patency was evaluated by clinical examination and
duplex ultrasonography. A total of 203 lesions (183 stenoses, 20 occlusions) were treated in 66 femoropopliteal and 69
infrapopliteal arterial segments. The TransAtlantic Inter-Societal Consensus (TASC) classification of the primary lesions
was A in 41.5%, B in 45.2%, C in 8.2%, and D 5.1%. Mean follow-up was 16.1 9.7 months. The overall technical success
rate was 96.3% and the complication rate was 8.9%. There were two (1.5%) perioperative deaths. The primary patency rate
was 82.1% at 12- and 24-months in patients with claudication (femoropopliteal lesions). The 1- and 2-year results for
femoropopliteal and infrapopliteal lesions in patients with CLI were: primary patency 64.4% and 51.9 %, respectively;
limb salvage 84.2% and 76.9%; survival 92.6% and 88.5%. More distal lesions and TASC classification were significant
independent risk factors for outcome (P < .05). Treatment of multiple segment lesions was an independent predictor of
a favorable outcome (P  .04).
Conclusion: CB-PTA is safe and feasible for the treatment of infrainguinal arterial occlusive disease, with relatively low
mid-term restenosis rates compared to other endovascular treatments. However, these data cannot be extrapolated to
potential outcomes for lesions>10 cm in length. Further follow-up will be necessary to evaluate the long-term results of
CB-PTA. (J Vasc Surg 2008;48:1182-8.)The role of percutaneous transluminal angioplasty
(PTA) has been established in the treatment of claudicant
patients with focal femoropopliteal disease during the past
decade.1,2 In a cost-effectiveness analysis, PTA was found
to be the preferred initial treatment in patients with dis-
abling claudication due to femoropopliteal arterial disease,3
in spite of some concern over the need for repeat PTA and
surgical revascularization to treat restenosis. PTA is safe and
feasible in patients with critical limb ischemia (CLI).4 Data
from the bypass vs angioplasty in severe ischemia of the leg
(BASIL) trial show the similar ability of bypass surgery and
balloon angioplasty to preserve both life and limb short-
term.5 However, elastic recoil and vessel wall injury during
dilation after infrainguinal PTA for peripheral arterial oc-
clusive disease (PAOD) may be a cause of limited durability
of angioplasty.
Cutting balloons (CB) are relatively new devices de-
signed for the percutaneous treatment of recurrent stenosis
due to neointimal hyperplasia within coronary artery
stents.6,7 The catheters have three or four microsurgical
blades mounted longitudinally on the balloon which cut
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1182directly into the stenotic lesion during initial balloon infla-
tion. Cutting balloon percutaneous transluminal angio-
plasty (CB-PTA) induces mechanical and biological effects
to reduce elastic recoil, vessel wall injury and potentially to
reduce restenosis. Compared to PTA, CB-PTA has been
shown to be effective in decreasing the inflammatory re-
sponse,8 endothelial damage,9 proliferative response,7 and
to achieve larger lumen areas.10 CBs are used increasingly
in settings where neointimal hyperplasia is present, partic-
ularly in hemodialysis fistula stenoses but more recently
with other graft anastomoses. With such new technology,
there is a tendency to reserve its use for stenoses resistant to
standard techniques.
The aim of this study was to evaluate the short- and
mid-term outcomes in terms of feasibility, safety, primary
patency, and limb salvage of CB-PTA used as primary “sole
therapy” for the treatment of PAOD.
METHODS
Patients. Data were collected prospectively on all con-
secutive patients who underwent CB-PTA to improve in-
frainguinal arterial circulation between January 2003 and
July 2007. Exclusion criteria included concomitant or se-
quential treatment of iliac lesions, and patients who under-
went concomitant aortoiliac or infrainguinal open bypass
surgery. During the same period, no other forms of infrain-
guinal angioplasty were performed.
The peripheral artery disease was evaluated by clinical
examination, ankle-brachial index (ABI) measurements,
duplex ultrasonography, and lower limb angiography in all
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50% on ultrasonography were considered to be hemody-
namically relevant. The occlusive lesions in the lower ex-
tremities were classified by angiographic findings according
to the TransAtlantic Inter-Societal Consensus (TASC).11
Stent placement was limited to patients with dissection
of femoropopliteal occlusive lesions after CB-PTA. No
stent was placed in infrapopliteal lesions.
The criteria for open bypass surgery as the primary
treatment for PAODwas long (10 cm) arterial occlusion.
Chronic CLI (Fontaine stages III or IV, Rutherford stages
IV-VI) was defined by persistently recurring rest pain re-
quiring regular analgesia for more than 14 days or by
nonhealing ulceration or gangrene of the foot or toes.
Intermittent claudication patients (Fontaine stage IIb,
Rutherford stage III) with femoropopliteal lesions required
intervention in the case of an incapacitating claudication
interfering with work or lifestyle after correction of risk
factors, exercise rehabilitation programs and optimal med-
ical therapy failure.
Technique. Angioplasty was performed in the operat-
ing room. The arterial access site was chosen to guarantee
the best accessibility to the lesion: ipsilateral or contralateral
femoral approach using various sizes of introducer sheaths
ranging from 6F to 7F. Femoral artery cutdown was per-
formed in case of failure of a percutaneous approach. Ad-
ministration of a 0.5 mg/kg bolus of heparin was per-
formed routinely after insertion of the introducer sheath.
To define the anatomy, diagnostic arteriography was per-
formed routinely before intervention. The lesion was
crossed using a 0.035-inch hydrophilic guide wire (Terumo
Europe, Leuven, Belgium). The guide wire was exchanged
for a dedicated 0.018-inch or 0.014-inch guide wire. CB-
PTA was performed with a CB selected to match the length
of the lesion and the diameter of the artery: the size range
from 2 to 6mm in diameter and 10 to 20mm in length.We
undersized the cutting balloon for the first angioplasty and
then we selected a greater CB diameter if necessary. No
oversizing was ever performed. CB-PTA was performed
with one to two overlapping inflations (maximum pressure
of 8 atm) and included the entire length of each stenotic
lesion. CB inflation and deflation have to be performed
gradually to allow extrusion and refolding of the blades in
and from their protective sleeves and to avoid tangling of
the microsurgical blades. All the CB-PTA were performed
without predilatation. In the average of an occlusion that
we were traversing, to know if it was transluminal or sub-
intimal a control angiography via a catheter angiography
was performed, after that the target occlusion was tra-
versed. CB-PTA was only performed if the lesion was
traversed transluminally.
Control arteriography was performed after each CB-
PTA and included the CB-PTA site and runoff vessels for
assessment of potential complications such as vasospasm,
dissection, thrombosis, or embolism. A significant dissec-
tion was present if extraluminal dye was present for a length
of greater than 15 mm.After CB-PTA, double antiplatelet treatment (aspirin
75 mg and clopidogrel) was administered if there were no
contraindications for 1 month and then a single antiplatelet
treatment (aspirin 75mg or clopidogrel 75mg) was admin-
istered routinely.
Criteria for success and follow-up. Success of PTA
was defined anatomically, hemodynamically, and clinically
according to the Society for Vascular Surgery and Interna-
tional Society for Cardiovascular Surgery reporting stan-
dards.12,13 (1) PTA was deemed technically successful if
there was 30% residual stenosis; (2) PTA was considered
as a clinical success/improvement if the symptoms im-
proved by at least one category together with an increase in
ABI of 0.10 (this constitutes primary clinical success
instead of continued or corrected clinical success after
successful reintervention); (3) patency was determined by
duplex scans, ABI measurements, or both; (4) all revi-
sions performed on the basis of the criteria described
previously or occlusion at any lesion on the same limb
were considered primary PTA failures; and (5) all analysis
was performed on an intent-to-treat basis, including
initial technical failures.
Patients were usually seen within 4 weeks after the
procedure. Postoperative follow-up (clinical examination,
ABI measurements, and serial duplex ultrasonography
scanning) was conducted every 3 months during the first
postoperative year and every 6 months thereafter.
Data analysis. The entire cohort was analyzed, as were
subgroups of patients with limiting claudication and those
with CLI. All the patients were analyzed in intention to
treat and, therefore, patients treated by a subsequent bypass
were considered to be a CB-PTA failure. Outcomes were
analyzed using Kaplan-Meier life-table analysis, the log-
rank test for survival curves, and the one-sample t test. A
Cox proportional hazard model was used to determine
whether presentation and level of disease were independent
predictors of outcome. Statistical significance was defined
as a P value  .05.
RESULTS
Demographic information. One-hundred thirty-five
limbs in 128 consecutive patients (87 men, 41 women;
mean age, 71.7  10.4 years) with PAOD (claudication
n 19; CLI n 116) were treated byCB-PTA (Table I). All
patients were primary cases. During the same period no
patients received standard balloon angioplasty and/or
stenting for infrainguinal lesions and infrainguinal bypasses
were performed in 156 patients. Indication for open sur-
gery was an occlusion longer than 10 cm or failure of
CB-PTA for all lesions10 cm in length. The prevalence of
risk factors of atherosclerosis in our CB-PTA cohort varied
from 14-83.6%, as shown in Table II. Of these patients, 93
(72.6%) had diabetes, 18 (14%) had renal disease, 107
(83.6%) had arterial hypertension, 57 (44.5%) were smok-
ers, and 95 (74.2%) had hyperlipidemia.
Altogether, 203 infrainguinal lesions (183 stenoses, 20
occlusions) were treated (Table I). The most distal affected
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ral and/or popliteal artery in 66 patients (48.9%; Femoro-
popliteal group), and the infrapopliteal arteries in 69
(51.1%; BelowKnee group).
In the BelowKnee group, concomitant proximal angio-
plasty was performed on 14 limbs (20.3%): in the superficial
femoral artery in seven (10.1%), in the popliteal artery in
four (5.8%), and in the superficial femoral and popliteal
artery femoropopliteal segment in three (4.4%); whereas in
55 limbs (79.7%) only the infrapopliteal arteries were
treated by PTA. The mean length of all treated segments
was 13.65  6.1 mm (range, 4-70 mm).
Initial success and early complications. An open
approach of the femoral artery was performed in 13% of the
cases. Most of the surgical approaches were performed at
the beginning of our experience. All 203 infrainguinal
lesions were dilated successfully. The primary angiographic
success rate for CB-PTA of stenoses and occlusions was
96.3%. Procedural mortality, defined as death within 30
days of the procedure, was 1.5% (2/128 patients). The
30-day mortality was always related to the overall medical
condition of the patient. Seven limbs (5.2%) underwent
major amputation within 30 days.
Intimal dissection occurred in five (3.7%) cases. In
order to maintain arterial blood flow, dissection of the
popliteal artery was treated successfully with an extended
inflation time with a non-cutting balloon (n  1), artery





Critical limb ischemia 116 86




Most distal artery treated
Femoropopliteal arteries (Femoropopliteal group) 66 48.9
Infrapopliteal arteries (BelowKnee group) 69 51.1
TASC classification
Type A 56 41.5
Type B 61 45.2
Type C 11 8.2
Type D 7 5.1
Table II. Characteristics of patients treated with
CB-PTA for de novo peripheral arterial lesions
n %
Arterial hypertension 107 83.6
Hyperlipidemia 95 74.2
Diabetes mellitus 93 72.6
Smoking 57 44.5
Chronic renal failure 18 14dissection in the superficial femoral artery was treated byimplantation of two stents (Wallstent, Boston Scientific,
Natick, Mass) (n  2), and artery dissection in the superfi-
cial femoral artery was treated by implantation of two
covered stents (Viabahn, W. L. Gore & Associates, Flag-
staff, Ariz) (n 2). CB-PTA required stent implantation in
only four (2.9%) cases. In a case of a severe calcified lesion,
one post-CB-PTA leak occurred without causing any mor-
bidity. Four groin hematoma that did not require surgical
treatment occurred. Two postoperative surgical site infec-
tions required surgical treatment. Hence, the overall com-
plication rate was 8.9% (n  12).
Mid-term success. The mean follow-up was 16.1 
9.7 months (range, 1-75 months). Two patients (1.5%)
were lost to follow-up. The overall survival rate for CLI at
1- and 2-years was, respectively, 92.6% and 88.5%. Primary
CB-PTA was followed by subsequent open bypass surgery
in 11 limbs (8.1%) for the purpose of limb salvage. A
subsequent bypass was performed if the critical ischemia
was persisting or recurring whether the target stenosis
remains patent or not. And therefore, the time between
CB-PTA and subsequent bypass was very different for all
the patients ranging from 1 day to 6 months after CB
angioplasty. A total of 20 limbs (14.8%), including five
within 30 days after PTA, underwent major amputation. Of
these 20 limbs, no distal bypass surgery was attempted
because of unreconstructable distal vessels (9) or advanced
gangrene and/or infection (4) or lack of autologous ve-
nous grafts (5).
The overall primary patency rates at 1- and 2-years were
64.4% and 51.9%, respectively (Fig 1). In the subgroup
claudication (n  19), the primary patency rates at 1- and
2-years were 82.1% (Fig 2). In the CLI subgroup (n 
116), the primary patency at rates 1- and 2-years were
64.4% and 51.9%, respectively (Fig 2); the limb salvage
rates at 1- and 2-years were 84.2% and 76.9%, respectively.
In the BelowKnee group, the primary patency rates at
1- and 2-years were 59.7% and 42.6%, respectively (Fig 3).
In the Femoropopliteal group, the primary patency rates at
Fig 1. Kaplan-Meier life-table analysis of overall primary patency
rate. S.E., Standard error.1- and 2-years were 75.2% (Table III, Fig 3).
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decreased the primary patency rate (P  .0268). Patients
with TASC type C or D had significantly decreased primary
patency rates (P .0475) (Fig 4). The primary patency rate
also increased with the number of segments treated (P 
.0407) (Fig 5). Arterial hypertension (P  .086) and
chronic renal failure (P .059) were not statistically signif-
Fig 2. Kaplan-Meier life-table analysis of primary patency accord-
ing to clinical stage of patients. CLI, Claudication or critical limb
ischemia; S.E., Standard error.
Fig 3. Kaplan-Meier life-table of primary patency with the most
distal affected arteries treated. FP, femoral superficial or popliteal
artery; BK, below the knee artery; S.E., standard error.icant factors.DISCUSSION
Endovascular treatment of infrainguinal lesions has
long been hindered by suboptimal patency rates. Conven-
tional angioplasty in particular has been limited by high
dissection rates and vascular recoil. Despite technical bal-
loon modifications and variations in technique, there has
been little progress in defeating the process of restenosis.
The current study demonstrates a high degree of tech-
nical success with CB-PTA used on a wide selection of
infrainguinal lesions. Angioplasty of infrainguinal lesions
has traditionally achieved technical and hemodynamic suc-
cess in 80% of cases.14 The technical success rate seen
with CBs in this trial was 96.3%, and significant dissection
was seen in only 3.7% of patients treated. Significant dissec-
tion rates in contemporary studies of angioplasty have been
reported to occur at a higher frequency than that observed
in our cohort.15
A few studies have reported the results of CB-PTA for
infrainguinal de novo arterial stenosis. The most important
series was that of Ansel et al,16 who reported procedural
outcomes at a mean of 1-year of follow-up in 73 patients
with symptomatic lower limb ischemia. In their series,
89.5% of threatened limbs were salvaged. This result is
similar to the rate described in our report, but a higher rate
of adjunctive stenting (20%) was required due to severe
intimal dissection or inadequate hemodynamics. Rabbi
et al,17 reported a series of 11 patients, with a primary
angiographic success rate for CB-PTA of 90.9%, a primary
patency rate at 3 months of 88%, and 100% of threatened
limbs salvaged. Amighi et al,18 reported the results of a
randomized controlled trial comparing PTA and CB-PTA
in superficial femoropopliteal artery lesions: CB-PTA did
not prove to be superior to conventional PTA. The rela-
tively small patient sample (43) and from the relatively
short follow-up period (6 months) in their study has to be
recognized as a limitation and, furthermore, the patient-
reported walking distance is not as objective as standard-
ized treadmill test results.
Conventional angioplasty in the superficial femoral ar-
tery and popliteal arteries for claudication has been shown
to have a patency rate of 37% at 1-year,19 whereas CB-PTA
resulted in a 1-year primary patency rate of 82.1%. The
limitations of conventional angioplasty of femoropopliteal
occlusive disease have led to the increasing use of stents in
an effort to achieve better outcomes. Despite the use of
stents, Schillinger et al,19 in a controlled prospective trial,
reported primary patency rates of only 63% at 1-year
whereas CB-PTA resulted in a 1-year primary patency rate
of 82.1%. The aggressive neointimal response to stent
implantation is well-understood, and problems such as
stent fracture and inflammatory reactions to endografts
have been reported. In our study, CB-PTA required stent
implantation in only 2.9% of cases. The use of a coated stent
did not make a significant difference in reducing target
vessel failure in de novo native femoropopliteal artery le-
sions compared to the use of uncoated stents.20
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However, the clinical advantages of angioplasty are well
established for the high-risk, elderly, and vascularly-
compromised patient: there is no need for general anesthesia,
and complication andmortality rates are low.21Despite a high
percentage of restenosis, PTA was reported to result in a
high rate of limb salvage. Our initial experience with con-
ventional angioplasty in the infrainguinal arteries for CLI
was disappointing because of poor primary patency. Our
results with CB-PTA for stent restenosis, in lesions resistant
to standard balloon angioplasty and for infrainguinal vein
bypass graft stenosis, have incited us to use CB-PTA in de




Claudication group 19 14.1
Critical limb ischemia group 116 85.9
Femoropopliteal group 66 48.9
BelowKnee group 69 51.1
Fig 4. Kaplan-Meier life-table analysis of primary patency accord-
ing to TASC classification. S.E., Standard error.novo infrainguinal arterial lesions in order to prevent reste-nosis. We initially limited the indication for CB-PTA to
patients unsuitable for open surgery. Our promising results
with CB-PTA have led us to consider CB-PTA as a first-line
procedure in patients with CLI whenever possible (with
multiple staged stenosis or occlusion less than 10 cm in
length) and to not limit the indication for CB-PTA to
patients who cannot undergo surgery. As a consequence,
bypass surgery is now considered as a second-line proce-
dure after PTA failure. Conventional angioplasty in the
infrainguinal arteries for CLI has been shown to have a
restenosis rate of 65% at 2-years,22 whereas CB-PTA
showed a restenosis rate of 48% at 2-years. One prospec-
tive study with lower limb ischemia reported that PTA and
bypass surgery achieved the same limb salvage rate of 76% at
1-year.23 Our study reports a higher limb salvage rate at
1-year (84.2%) than for PTA. Additionally, failure of CB-
PTA or PTA does not preclude the possibility of perform-
ing subsequent bypass grafting.
Several potential mechanisms of action may have con-
vo peripheral artery lesions in each subgroup
Primary patency (%) Limb salvage (%)
onths 24 months 12 months 24 months
4.4 51.9
2.1 82.1
4.4 51.9 84.2 76.9
5.2 75.2
9.7 42.6 80.2 70.2
Fig 5. Kaplan-Meier life-table analysis of primary patency in pa-






7tributed to the CB results obtained in this study. The
atera
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plasty has been strongly linked to restenosis. It stands to
reason that if the vascular injury is more localized for
achieving vessel dilation, angioplasty would therefore be
accompanied by less reactivity. Theoretically, this device
induces a smaller degree of vessel wall injury localized to the
area of incision and sparing the interincisional segments.
The response of the artery to balloon dilation can be
divided into four phases, each of which contributes to
restenosis: (1) the mechanical phase, which may be compli-
cated by early elastic recoil; (2) the thrombogenic phase,
which is characterized by mural thrombus formation sec-
ondary to local hemorrhage and thrombosis; (3) the pro-
liferative phase, which is typified by neointimal hyperpla-
sia; and (4) the remodeling phase, with pathological
changes in the cellular and protein content of the media
and adventitia.
The fact that more than one vessel were recanalized in
the same setting could be an explanation for a better
outcome or improved results. The aim for performing
CB-PTA of more than one lesion is to improve the run-off
and, therefore, decreases the risk of restenosis related to the
fact that poor runoff was reported as a variable predicting
restenosis.24
Therapeutic anticoagulation and antiplatelet therapy
are used to prevent thrombosis during the thrombogenic
phase. CB-PTA has been shown to decrease the inflamma-
tory8 and proliferative responses,9 and also decreases endo-
thelial damage leading to faster endothelialization.7 Fur-
thermore, it has been shown that CB-PTA increases in
patent lumens caused by either positive remodeling or
Fig 6. Recanalization by CB-PTA of the anterior tibial
posterior tibial artery outflow and retention of open collplaque reduction.10 This was suggestive of an additionalmechanism of CB-plaque reduction, which was also con-
tributed to the larger lumen areas when CB-PTA was
compared with PTA before stent placement. Thus, the
association of antiplatelet therapy and CB-PTA could re-
duce the negative side-effects of the four phases that con-
tribute to restenosis due to the response of the artery to
balloon dilation.
One concern regarding endovascular angioplasty is its
uncertain durability, and whether patients will become
clinically worse than they were before the procedure in the
event of target site restenosis or occlusions. CB-PTA com-
pared with subintimal angioplasty or PTAwith stenting can
maintain the collaterals within the segments proximal and
distal to the stenosis open and could prevent patients from
becoming clinically worse than they were before the proce-
dure (Fig 6).
The CB should be used with caution due to possible
complications caused by its unique design. The greatest
cause for concern after CB-PTA is vessel rupture, but this
has been reported rarely after arterial CB-PTA. In the
coronary global randomized trial,25 the incidence was 0.8%
(5/689 patients) compared with 0% after standard coro-
nary angioplasty. In accordance with the instruction man-
ual, dilation as well as deflation should be performed slowly
to allow extrusion and refolding of the blades in and from
their protective sleeves. If not performed according to
instructions, blade dislodgement may occur. Garvin et al,26
showed a higher complication rate with CB-PTA for in-
frainguinal vein bypasses. Infrainguinal vein bypass steno-
sis is very different from infrainguinal arterial stenosis
and thus may be associated with a higher rate of compli-
, pedal artery, and fibular artery leading to restoration of
ls.arterycations. Furthermore, the choice of the diameter of the
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ting balloon correlates with greater risk of rupture than
standard balloon.
Our statistical analysis indicated that more distal lesions
and TASC type C or D were significant independent pre-
dictors of worse long-term results. On the other hand, the
greater the number of segments treated (1) the higher
the primary patency rate.
The cost of the CB ($800 US) is higher than standard
balloon but less than peripheral stent. In our experience,
the CB-PTA may be cost-effective related to the fact that
associated with a lower rate of restenosis and, therefore,
associated with a lower rate of reintervention.
These data demonstrate that the CB is a safe and
feasible option for the treatment of infrainguinal arterial
occlusive disease with relatively low mid-term restenosis
rates compared to other types of endovascular treatment.
Furthermore, failure of CB-PTA does not preclude the
possibility of performing subsequent bypass grafting. How-
ever, these data cannot be extrapolated to potential out-
comes for lesions10 cm in length. Further follow-up will
be necessary to evaluate the long-term results of CB-PTA.
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